ADAMTS12 promotes fibrosis by restructuring extracellular matrix to enable activation of injury-responsive fibroblasts.


Journal

The Journal of clinical investigation
ISSN: 1558-8238
Titre abrégé: J Clin Invest
Pays: United States
ID NLM: 7802877

Informations de publication

Date de publication:
17 Sep 2024
Historique:
received: 08 03 2023
accepted: 10 07 2024
medline: 17 9 2024
pubmed: 17 9 2024
entrez: 17 9 2024
Statut: epublish

Résumé

Fibrosis represents the uncontrolled replacement of parenchymal tissue with extracellular matrix (ECM) produced by myofibroblasts. While genetic fate-tracing and single-cell RNA-Seq technologies have helped elucidate fibroblast heterogeneity and ontogeny beyond fibroblast to myofibroblast differentiation, newly identified fibroblast populations remain ill defined, with respect to both the molecular cues driving their differentiation and their subsequent role in fibrosis. Using an unbiased approach, we identified the metalloprotease ADAMTS12 as a fibroblast-specific gene that is strongly upregulated during active fibrogenesis in humans and mice. Functional in vivo KO studies in mice confirmed that Adamts12 was critical during fibrogenesis in both heart and kidney. Mechanistically, using a combination of spatial transcriptomics and expression of catalytically active or inactive ADAMTS12, we demonstrated that the active protease of ADAMTS12 shaped ECM composition and cleaved hemicentin 1 (HMCN1) to enable the activation and migration of a distinct injury-responsive fibroblast subset defined by aberrant high JAK/STAT signaling.

Identifiants

pubmed: 39286973
pii: 170246
doi: 10.1172/JCI170246
doi:
pii:

Substances chimiques

ADAMTS Proteins EC 3.4.24.-

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Konrad Hoeft (K)

Department of Medicine 2 (Nephrology, Rheumatology, Clinical Immunology and Hypertension), RWTH Aachen University, Medical Faculty, Aachen, Germany.

Lars Koch (L)

Department of Medicine 2 (Nephrology, Rheumatology, Clinical Immunology and Hypertension), RWTH Aachen University, Medical Faculty, Aachen, Germany.

Susanne Ziegler (S)

Department of Medicine 2 (Nephrology, Rheumatology, Clinical Immunology and Hypertension), RWTH Aachen University, Medical Faculty, Aachen, Germany.

Ling Zhang (L)

Department of Medicine 2 (Nephrology, Rheumatology, Clinical Immunology and Hypertension), RWTH Aachen University, Medical Faculty, Aachen, Germany.

Steffen Luetke (S)

Department of Pediatrics and Adolescent Medicine.
Center for Biochemistry, Medical Faculty, and.
Center for Molecular Medicine Cologne, University of Cologne, Cologne, Germany.
Cologne Center for Musculoskeletal Biomechanics (CCMB), Cologne, Germany.

Maria C Tanzer (MC)

The Walter and Eliza Hall Institute of Medical Research, Melbourne, Victoria, Australia.
Department of Medical Biology, University of Melbourne, Melbourne, Victoria, Australia.
Max-Planck Institute of Biochemistry, Martinsried, Germany.

Debashish Mohanta (D)

Department of Medicine 2 (Nephrology, Rheumatology, Clinical Immunology and Hypertension), RWTH Aachen University, Medical Faculty, Aachen, Germany.

David Schumacher (D)

Department of Medicine 2 (Nephrology, Rheumatology, Clinical Immunology and Hypertension), RWTH Aachen University, Medical Faculty, Aachen, Germany.
Department of Anesthesiology, RWTH Aachen University, Aachen, Germany.

Felix Schreibing (F)

Department of Medicine 2 (Nephrology, Rheumatology, Clinical Immunology and Hypertension), RWTH Aachen University, Medical Faculty, Aachen, Germany.
Sequantrix GmbH, Aachen, Germany.

Qingqing Long (Q)

Department of Medicine 2 (Nephrology, Rheumatology, Clinical Immunology and Hypertension), RWTH Aachen University, Medical Faculty, Aachen, Germany.

Hyojin Kim (H)

Department of Medicine 2 (Nephrology, Rheumatology, Clinical Immunology and Hypertension), RWTH Aachen University, Medical Faculty, Aachen, Germany.

Barbara M Klinkhammer (BM)

Institute of Pathology, RWTH Aachen University, Aachen, Germany.

Carla Schikarski (C)

Department of Medicine 2 (Nephrology, Rheumatology, Clinical Immunology and Hypertension), RWTH Aachen University, Medical Faculty, Aachen, Germany.

Sidrah Maryam (S)

Department of Medicine 2 (Nephrology, Rheumatology, Clinical Immunology and Hypertension), RWTH Aachen University, Medical Faculty, Aachen, Germany.

Mathijs Baens (M)

CISTIM Leuven vzw, Leuven, Belgium.

Juliane Hermann (J)

Institute for Molecular Cardiovascular Research, RWTH Aachen University, Medical Faculty, Aachen, Germany.

Sarah Krieg (S)

Institute of Biochemistry and Molecular Biology, and.

Fabian Peisker (F)

Department of Medicine 2 (Nephrology, Rheumatology, Clinical Immunology and Hypertension), RWTH Aachen University, Medical Faculty, Aachen, Germany.

Laura De Laporte (L)

Institute of Technical and Macromolecular Chemistry, RWTH Aachen University, Aachen, Germany.
Institute of Applied Medical Engineering, Department of Advanced Materials for Medicine, University Hospital RWTH Aachen, Aachen, Germany.
DWI-Leibniz Institute of Interactive Materials, Aachen, Germany.

Gideon Jl Schaefer (GJ)

Department of Medicine 2 (Nephrology, Rheumatology, Clinical Immunology and Hypertension), RWTH Aachen University, Medical Faculty, Aachen, Germany.

Sylvia Menzel (S)

Department of Medicine 2 (Nephrology, Rheumatology, Clinical Immunology and Hypertension), RWTH Aachen University, Medical Faculty, Aachen, Germany.

Joachim Jankowski (J)

Institute for Molecular Cardiovascular Research, RWTH Aachen University, Medical Faculty, Aachen, Germany.

Benjamin D Humphreys (BD)

Division of Nephrology, Department of Medicine, Washington University in St. Louis, St. Louis, Missouri, USA.

Adam Wahida (A)

Institute of Metabolism and Cell Death, Helmholtz Zentrum München, Neuherberg, Germany.

Rebekka K Schneider (RK)

Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
Department of Cell Biology, Institute for Biomedical Technologies, RWTH Aachen University, Aachen, Germany.

Matthias Versele (M)

CISTIM Leuven vzw, Leuven, Belgium.

Peter Boor (P)

Department of Medicine 2 (Nephrology, Rheumatology, Clinical Immunology and Hypertension), RWTH Aachen University, Medical Faculty, Aachen, Germany.
Institute of Pathology, RWTH Aachen University, Aachen, Germany.

Matthias Mann (M)

Max-Planck Institute of Biochemistry, Martinsried, Germany.

Gerhard Sengle (G)

Department of Pediatrics and Adolescent Medicine.
Center for Biochemistry, Medical Faculty, and.
Center for Molecular Medicine Cologne, University of Cologne, Cologne, Germany.
Cologne Center for Musculoskeletal Biomechanics (CCMB), Cologne, Germany.

Sikander Hayat (S)

Department of Medicine 2 (Nephrology, Rheumatology, Clinical Immunology and Hypertension), RWTH Aachen University, Medical Faculty, Aachen, Germany.

Rafael Kramann (R)

Department of Medicine 2 (Nephrology, Rheumatology, Clinical Immunology and Hypertension), RWTH Aachen University, Medical Faculty, Aachen, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH